SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.
"We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives” said John Orwin, Chief Executive Officer. "Together, Stacey and Steve bring over 40 years of industry experience across a variety of corporate functions, including research, technical operations, manufacturing, corporate development and finance. Their expertise will be invaluable to Atreca as we continue to advance ATRC-101 and build our preclinical pipeline.”
Dr. Stacey Ma
Dr. Ma is currently the Executive Vice President and Head of Technical Operations at Sana Biotechnology, a publicly listed biotechnology company, where she has served since March 2019. From 1996 to 2019, she served various roles at Genentech/Roche, a biotechnology company, including as their Global Head of Innovation, Manufacturing Science and Technology from March 2018 to March 2019, and as Vice President, Global Head of Investigational Medicinal Products (IMP) Quality from May 2015 to February 2018. From July 1996 to May 2015, she held various other roles related to analytical development, pharmaceutical development, quality, technical product management and supply chain.
Stephen R. Brady
Mr. Brady is currently the Chief Executive Officer of Tempest Therapeutics, a publicly listed biotechnology company. Previously, he served as the President and Chief Operating Officer at Tempest from September 2019 to June 2021. Prior to joining Tempest, he served in various leadership roles at Immune Design Corp., including as Executive Vice President, Strategy & Finance from May 2015 until its sale to Merck in 2019, and as Chief Business Officer from September 2013 to May 2015. Prior to Immune Design, Mr. Brady served in various leadership roles at 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.), including as Chief Business Officer from February 2011 to August 2013, and as Vice President, Corporate Development, Strategy and Operations from February 2010 to February 2011. From April 2007 to March 2010, Mr. Brady held various roles at Proteolix, Inc., most recently serving as Vice President of Corporate Development.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. The statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, and the availability and timing of data from the Phase 1b trial of ATRC-101. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, and the implementation of our strategic plans for our business, technologies, and current and potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251
agray@atreca.com
Media:
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Source: Atreca, Inc.